Johnson & Johnson (JNJ) Q2 2025 Earnings Call Transcript

Image source: The Motley Fool.Need a quote from one of our analysts? Email pr@fool.comJohnson & Johnson (NYSE:JNJ) highlighted 4.6% operational sales growth and $23.7 billion in quarterly sales, with over $15 billion in quarterly innovative medicine revenue accomplished for the first time despite large STELARRA headwinds. The innovative medicine segment demonstrated resilience through double-digit growth in thirteen brands, significant oncology and immunology expansion, and continued strategic execution in neuroscience bolstered by acquisitions such as Intracellular Therapies. MedTech outpaced recent quarters, with particular momentum in cardiovascular and new surgical technologies, while operating segment margins experienced pressure from product mix and external cost factors. Guidance for both full-year sales and earnings per share was raised, reflecting strong business fundamentals, expected approval catalysts, and favorable foreign currency impacts, with free cash flow and capital position supporting ongoing R&D investment.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool